# Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

> **NCT03202147** · PHASE2 · WITHDRAWN · sponsor: **AZTherapies, Inc.**

## Conditions studied

- Ischemic Stroke
- Post-stroke Cognitive Impairment

## Interventions

- **DRUG:** Cromolyn
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03202147
- **Lead sponsor:** AZTherapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study halted prematurely prior to initiation but potentially will resume in the future.
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202147, "Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03202147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*